7 research outputs found
Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries
BACKGROUND: There is little information about familial hypercholesterolemia (FH) epidemiology
and care in Ibero-American countries. The Ibero-American FH network aims at reducing the gap on
diagnosis and treatment of this disease in the region.
OBJECTIVE: To describe clinical, molecular, and organizational characteristics of FH diagnosis in
Argentina, Brazil, Chile, Colombia, Mexico, Portugal, Spain, and Uruguay.
METHODS: Descriptive analysis of country data related to FH cascade screening, molecular diagnosis,
clinical practice guidelines, and patient organization presence in Ibero-America.
RESULTS: From a conservative estimation of an FH prevalence of 1 of 500 individuals, there should
be 1.2 million heterozygous FH individuals in Ibero-America and roughly 27,400 were diagnosed so
far. Only Spain, Brazil, Portugal, and Uruguay have active cascade screening programs. The prevalence
of cardiovascular disease ranged from 10% to 42% in member countries, and the highest molecular
identification rates are seen in Spain, 8.3%, followed by Portugal, 3.8%, and Uruguay with 2.5%. In
the 3 countries with more FH patients identified (Spain, Portugal, and Brazil) between 10 and 15 mutations
are responsible for 30% to 47% of all FH cases. Spain and Portugal share 5 of the 10 most common
mutations (4 in low density lipoprotein receptor [LDLR] and the APOB3527). Spain and Spanishspeaking
Latin American countries share 6 of the most common LDLR mutations and the APOB3527.
LDL apheresis is available only in Spain and Portugal and not all countries have specific FH diagnostic
and treatment guidelines as well as patient organizations.
CONCLUSIONS: Ibero-American countries share similar mutations and gaps in FH care.info:eu-repo/semantics/publishedVersio
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60 countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed. © 2018 Elsevier B.V
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed. © 2018 Elsevier B.V